Search Login Register
Histocompatibility Antigens Class I
Summary
Description:
Large transmembrane, polymorphic glycoproteins noncovalently associated with nonpolymorphic beta 2-microglobulin. In humans, three structural genes on chromosome 6 code for the HLA-A; HLA-B and HLA-C antigens. In mice, three genes named K, D, and L on chromosome 17 code for the H-2 antigens. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during graft rejection and restrict cell-mediated lysis of virus-infected cells. They are primarily associated with rheumatologic diseases and certain malignant disorders.
Also Known As:
Class I Histocompatibility Antigens; Class I Human Antigens; Class I Major Histocompatibility Antigens; Human Class I Antigens; Antigens, Class I Show All >>
Networked: 587
relevant articles (11 outcomes,
42 trials/studies)
for this Bio-Agent
Key Diseases for which Histocompatibility Antigens Class I is
Relevant
-
Neoplasms (Cancer)
:
6 outcomes 12 studies in 204 results
-
Melanoma (Melanoma, Malignant)
:
2 outcomes 9 studies in 64 results
-
Neuroblastoma
:
1 outcome 1 study in 8 results
-
Colonic Neoplasms (Colon Cancer)
:
1 outcome in 5 results
-
B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
:
1 outcome in 3 results
Show All >>
Drugs Related to Histocompatibility Antigens Class I
-
Antigens
-
Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
-
DNA (Deoxyribonucleic Acid)
-
HLA-A Antigens (HLA-A)
-
Peptides
-
Protein Sorting Signals (Signal Peptide)
-
Antibodies
-
Immunoglobulins (Immunoglobulin)
-
I-antigen
-
Cell Adhesion Molecules
Show All >>
Therapies Related to Histocompatibility Antigens Class I
-
Transplants (Transplant)
-
Immunotherapy
-
Homologous Transplantation (Allograft)
-
Aftercare (After-Treatment)
-
Heterologous Transplantation (Xenotransplantation)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.